Evidence map›Paper›PMID 36153965›Full record

ArticleACS chemical biology2022

Identification of the Allosteric Binding Site for Thiazolopyrimidine on the C-Type Lectin Langerin.

Hengxi Zhang, Carlos Modenutti, Yelha Phani Kumar Nekkanti, Maxime Denis, Iris A Bermejo, Jonathan Lefèbre, Kateryna Che, Dongyoon Kim, Marten Kagelmacher, Dennis Kurzbach and 2 more

Open access · hybridAbstract read
In one paragraph

Article in ACS chemical biology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.0field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 13 citations in OpenAlex.

  1. Synthetic Ligands of Myeloid C-Type Lectin Receptors.Chembiochem : a European journal of chemical biology · 2026
    Review
  2. Article
  3. Article
  4. Article
  5. Secondary Sites of the C-type Lectin-Like Fold.Chemistry (Weinheim an der Bergstrasse, Germany) · 2024
    Review
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 3 countries.

Hengxi ZhangBiomolecular Systems, Max Planck Institute of Colloids and Interfaces, Am Mühlenberg 1 14424 Potsdam, Germany.
Carlos ModenuttiBiomolecular Systems, Max Planck Institute of Colloids and Interfaces, Am Mühlenberg 1 14424 Potsdam, Germany.
Yelha Phani Kumar NekkantiLeibniz Forschungsinstitut für Molekulare Pharmakologie (FMP), Robert-Roessle-Strasse 10, 13125 Berlin, Germany.
Maxime DenisDepartment of Pharmaceutical Sciences, University of Vienna, Josef-Holaubek-Platz 2, 1090 Vienna, Austria.
Iris A BermejoDepartment of Pharmaceutical Sciences, University of Vienna, Josef-Holaubek-Platz 2, 1090 Vienna, Austria.ORCID 0000-0001-8864-4852
Jonathan LefèbreDepartment of Pharmaceutical Sciences, University of Vienna, Josef-Holaubek-Platz 2, 1090 Vienna, Austria.
Kateryna CheFaculty of Chemistry, Institute of Biological Chemistry, University of Vienna, Währinger Straße 38, 1090 Vienna, Austria.
Dongyoon KimBiomolecular Systems, Max Planck Institute of Colloids and Interfaces, Am Mühlenberg 1 14424 Potsdam, Germany.
Marten KagelmacherBiomolecular Systems, Max Planck Institute of Colloids and Interfaces, Am Mühlenberg 1 14424 Potsdam, Germany.
Dennis KurzbachFaculty of Chemistry, Institute of Biological Chemistry, University of Vienna, Währinger Straße 38, 1090 Vienna, Austria.ORCID 0000-0001-6455-2136
Marc NazaréLeibniz Forschungsinstitut für Molekulare Pharmakologie (FMP), Robert-Roessle-Strasse 10, 13125 Berlin, Germany.ORCID 0000-0002-1602-2330
Christoph RademacherBiomolecular Systems, Max Planck Institute of Colloids and Interfaces, Am Mühlenberg 1 14424 Potsdam, Germany.ORCID 0000-0001-7082-7239
University of Vienna · ATLeibniz-Forschungsinstitut für Molekulare Pharmakologie · DEConsejo Nacional de Investigaciones Científicas y Técnicas · ARMax Planck Institute of Colloids and Interfaces · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Langerin is a mammalian C-type lectin expressed on Langerhans cells in the skin. As an innate immune cell receptor, Langerin is involved in coordinating innate and adaptive immune responses against various incoming threats. We have previously reported a series of thiazolopyrimidines as murine Langerin ligands. Prompted by the observation that its human homologue exhibits different binding specificities for these small molecules, we report here our investigations to define their exact binding site. By using structural comparison and molecular dynamics simulations, we showed that the nonconserved short loops have a high degree of conformational flexibility between the human and murine homologues. Sequence analysis and mutational studies indicated that a pair of residues are essential for the recognition of the thiazolopyrimidines. Taking solvent paramagnetic relaxation enhancement NMR studies together with a series of peptides occupying the same site, we could define the cleft between the short and long loops as the allosteric binding site for these aromatic heterocycles.

Indexed as

Lectins, C-TypeMannose-Binding LectinsAllosteric SiteAnimalsAntigens, CDBinding SitesHumansLigandsMammalsMiceSolventsAntigens, CDLectins, C-TypeLigandsMannose-Binding LectinsSolvents

Identifiers

PMID36153965
PMCPMC9594047
OpenAlexW4297239664

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.